title: PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis.
abstract: This meta-analysis aims at assessing the correlation of PD-L1 levels and response PD-1/PD-L1 inhibitors in advanced malignant melanoma.
  
  
  
  Eligible studies included those evaluating PD-1/PD-L1 inhibitors in advanced melanoma and correlating the outcomes to PD-L1 levels.
  
  
  
  After preclusion of ineligible studies, 11 studies were included. For PD-L1 >1% patients versus PD-L1 <1% patients treated with PD-1/PD-L1 targeted agents, the OR of ORR was 2.81 (95% CI: 1.64-4.82; p = 0.0002); while for PD-L1 >5% patients versus PD-L1 <5% patients, it was 2.22 (95% CI: 1.71-2.87; p < 0.00001).
  
  
  
  The current analysis indicates the value of PD-L1 positivity in predicting higher response from PD-1/PD-L1 agents. This molecular predictor - together with other predictors - may help further individualize treatment options for metastatic melanoma patients.
authors.affiliation: Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
authors.forename: Omar
authors.initials: O
authors.lastname: Abdel-Rahman
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D060890:B7-H1 Antigen / Q000276:immunology / Q000378:metabolism*; D054316:Biomarkers, Pharmacological / Q000378:metabolism; D002986:Clinical Trials as Topic; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008545:Melanoma / Q000276:immunology / Q000628:therapy*; D057285:Precision Medicine; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology / Q000378:metabolism*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D060890:B7-H1 Antigen; D054316:Biomarkers, Pharmacological; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor
keywords: PD-1; PD-L1; melanoma; nivolumab; pembrolizumab